AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37723108 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely administered adherence programme
Number of subjects: 0
Study 37723108 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37723113 — intervention group
Group type: EXPERIMENTAL
Intervention: GAMAD diagnostic model based on gender, age, multitarget circulating tumour DNA methylation signature and serological biomarkers (AFP, DCP)
Number of subjects: 2000
Study 37723113 — intervention group
Group type: COMPARATOR
Intervention: Standard imaging techniques and serum markers (not specified)
Number of subjects: 2000
Study 37723115 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sCLEC-2 levels measured at first visit and 7 days later or at discharge in patients with AIS/TIA
Number of subjects: 600
Study 37723115 — intervention group
Group type: EXPERIMENTAL
Intervention: sCLEC-2/D-dimer ratio
Number of subjects: 600
Study 37723115 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sCLEC-2
Number of subjects: 600
Study 37723198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived-xenograft (PDX) models established in immunocompromised mice
Number of subjects: 131
Study 37723198 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology, whole exome and RNA sequencing
Number of subjects: 131
Study 37723198 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular characterization of patients
Number of subjects: 131
Study 37723198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing of 90 models with IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform
Number of subjects: 131
Study 37723272 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week parent support program with follow-up booster sessions (PGB)
Number of subjects: 171
Study 37723272 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week parent support program without follow-up booster sessions (PGNB)
Number of subjects: 171
Study 37723272 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient treatment (ST)
Number of subjects: 171
Study 37723272 — intervention group
Group type: EXPERIMENTAL
Intervention: %IOTF25 for PGB
Number of subjects: 171
Study 37723272 — intervention group
Group type: COMPARATOR
Intervention: %IOTF25 for ST
Number of subjects: 171
Study 37723356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 0
Study 37723356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37723430 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-provided orientation of birth companions
Number of subjects: 475
Study 37723430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no midwife-provided orientation)
Number of subjects: 475
Study 37723439 — intervention group
Group type: EXPERIMENTAL
Intervention: GALAD score and semi-annual abdominal ultrasound for five years
Number of subjects: 1600
Study 37723439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 1600
Study 37723439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI annually for five years
Number of subjects: 1600
Study 37723439 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap resampling technique and Cox proportional hazards regression model
Number of subjects: 1600
Study 37723467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 220
Study 37723467 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic medication
Number of subjects: 220
Study 37723498 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation strategies (specific details not provided)
Number of subjects: 2479
Study 37723516 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-thoracoscopy
Number of subjects: 259
Study 37723516 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 259
Study 37723577 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg QD
Number of subjects: 420
Study 37723577 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Upadacitinib
Number of subjects: 420
Study 37723590 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cabozantinib and nivolumab
Number of subjects: 15
Study 37723837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus anlotinib
Number of subjects: 21
Study 37724431 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivette® Cortisol (SC)
Number of subjects: 0
Study 37724431 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal swabbing
Number of subjects: 0
Study 37724527 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics for 7 consecutive days
Number of subjects: 92
Study 37724527 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 consecutive days
Number of subjects: 92
Study 37724785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LIRT-BFR)
Number of subjects: 32
Study 37724785 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance training (HIRT)
Number of subjects: 32
Study 37725026 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal boost with D98% of 95 Gy
Number of subjects: 526
Study 37725026 — intervention group
Group type: COMPARATOR
Intervention: Standard whole-gland radiation therapy of 77 Gy
Number of subjects: 526
Study 37725082 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0
Study 37725082 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 37725234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9 mm diameter bone-level-tapered implant
Number of subjects: 41
Study 37725409 — intervention group
Group type: EXPERIMENTAL
Intervention: Full version of MASI app
Number of subjects: 50
Study 37725409 — intervention group
Group type: COMPARATOR
Intervention: Information-only version of the app
Number of subjects: 50
Study 37725429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support health education program
Number of subjects: 60
Study 37725490 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based muscle metrics analysis using machine learning algorithms and human quality assurance
Number of subjects: 3804
Study 37725490 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based muscle metrics analysis
Number of subjects: 3804
Study 37725576 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 15
Study 37725576 — intervention group
Group type: EXPERIMENTAL
Intervention: Targetable genomic alterations affecting PDGFRA
Number of subjects: 15
Study 37725576 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGFRA mutation p.D842N
Number of subjects: 15
Study 37725613 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose physical therapy intervention initiated in the NICU and continuing to 12 months of age, with twice-weekly sessions and caregiver-guided activities
Number of subjects: 192
Study 37725613 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 192
Study 37725680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide treatment in decompensated heart failure
Number of subjects: 2680
Study 37725919 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (8.4-33.6 g/day for 12 months)
Number of subjects: 304
Study 37725919 — intervention group
Group type: COMPARATOR
Intervention: Control (Salford Kidney Study cohort)
Number of subjects: 304
Study 37726068 — intervention group
Group type: EXPERIMENTAL
Intervention: Miracle fruit (MF) tablet
Number of subjects: 50
Study 37726068 — intervention group
Group type: COMPARATOR
Intervention: Placebo-sugar candy
Number of subjects: 50
Study 37726122 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation in language of origin and Norwegian
Number of subjects: 11347
Study 37726122 — intervention group
Group type: COMPARATOR
Intervention: Norwegian only
Number of subjects: 11347
Study 37726298 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib-lenalidomide-dexamethasone (IRd) following three cycles of bortezomib-based induction
Number of subjects: 140
Study 37726457 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kVp and 70-kVp tube voltage with adapted tube current
Number of subjects: 170
Study 37726457 — intervention group
Group type: COMPARATOR
Intervention: Standard 120-kVp protocol
Number of subjects: 170
Study 37726656 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-performed dietary sodium restriction (two weeks)
Number of subjects: 15
Study 37726656 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (two weeks)
Number of subjects: 15
Study 37726660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue oxygen saturation monitoring using near-infrared spectroscopy
Number of subjects: 99
Study 37726660 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline-3 SD tissue oxygen saturation threshold
Number of subjects: 99
Study 37726660 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline-2.5 SD tissue oxygen saturation threshold
Number of subjects: 99
Study 37726660 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected significance for baseline-3 SD and baseline-2.5 SD
Number of subjects: 99
Study 37726677 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) for 11 weeks
Number of subjects: 67
Study 37726677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in physical exercise habits)
Number of subjects: 67
Study 37726689 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced PRF plus with the recurrent application of C-PRF inside the socket every two weeks for 2 months (four times)
Number of subjects: 20
Study 37726689 — intervention group
Group type: COMPARATOR
Intervention: Advanced PRF plus alone
Number of subjects: 20
Study 37726695 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1 directed immunotherapy, IV infusion, 1680 mg, every 28 days for one year if tolerated)
Number of subjects: 33
Study 37726695 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1 directed immunotherapy)
Number of subjects: 33
Study 37726771 — intervention group
Group type: EXPERIMENTAL
Intervention: Education Outside the Classroom (EOtC) intervention: a two-day training course for teachers followed by implementation of EOtC >5 hours weekly over one school year.
Number of subjects: 54
Study 37726771 — intervention group
Group type: COMPARATOR
Intervention: Control group: 15 schools not receiving the EOtC intervention (waitlist control).
Number of subjects: 54
Study 37726786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived tumor organoids (PDTO) cultured in a medium supplemented with growth factors and signal pathway inhibitors.
Number of subjects: 0
Study 37726786 — intervention group
Group type: EXPERIMENTAL
Intervention: PDTO response to chemo-ICB (immune checkpoint blocker and chemotherapy).
Number of subjects: 0
Study 37726786 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility of generating PDTO from TNBC.
Number of subjects: 0
Study 37726786 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a living biobank of TNBC PDTO.
Number of subjects: 0
Study 37726806 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoUrine test for bladder cancer diagnosis; tested 47 samples.
Number of subjects: 203
Study 37726806 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoUrine test for recurrence diagnosis; tested 93 samples.
Number of subjects: 203
Study 37726806 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoUrine test predicting recurrence during follow-up.
Number of subjects: 203
Study 37726806 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of OncoUrine test result with recurrence free survival (RFS) of NMIBC patients.
Number of subjects: 203
Study 37726820 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrate
Number of subjects: 112
Study 37726820 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based omega fatty acid supplement
Number of subjects: 112
Study 37726820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplements combined
Number of subjects: 112
Study 37726820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 37726821 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIDGE (DBT + parenting skills)
Number of subjects: 180
Study 37726821 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT skills training
Number of subjects: 180
Study 37726821 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual
Number of subjects: 180
Study 37726823 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI) alone
Number of subjects: 450
Study 37726823 — intervention group
Group type: EXPERIMENTAL
Intervention: BNI plus facilitated initiation of medications for alcohol use disorder (BNI + MAUD)
Number of subjects: 450
Study 37726823 — intervention group
Group type: EXPERIMENTAL
Intervention: BNI + MAUD + initiation of computer-based training for cognitive behavioral therapy (CBT4CBT)
Number of subjects: 450
Study 37726823 — intervention group
Group type: COMPARATOR
Intervention: BNI alone, BNI + MAUD, BNI + MAUD + CBT4CBT
Number of subjects: 450
Study 37726843 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus surgical site infections (SSI) identified by semi-automated crossmatching bacteriological and electronic health record data.
Number of subjects: 178902
Study 37726843 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-specific incidence of S. aureus SSI across all surgical specialties.
Number of subjects: 178902
Study 37726843 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated approach to utilize big data in epidemiological studies.
Number of subjects: 178902
Study 37726848 — intervention group
Group type: EXPERIMENTAL
Intervention: BANG smartphone application (24-week eHealth program)
Number of subjects: 19
Study 37726889 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Program (telemedicine pain intervention)
Number of subjects: 20
Study 37727203 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based lifestyle intervention (nutrition and exercise)
Number of subjects: 20
Study 37727387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative slow-release dexamethasone intravitreal implant (Ozurdex)
Number of subjects: 0
Study 37727387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone implant)
Number of subjects: 0
Study 37727600 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 3795
Study 37727600 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety assessed using the Generalized Anxiety Disorder 7-item scale
Number of subjects: 3795
Study 37727600 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness assessed using the UCLA 3-item scale
Number of subjects: 3795
Study 37727600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition assessed using the Montreal Cognitive Assessment 5-Minute Protocol
Number of subjects: 3795
Study 37727608 — intervention group
Group type: EXPERIMENTAL
Intervention: BHOMA intervention (intensive clinical training, quality improvement measures, support for commodities procurement, improved community outreach, and district level management support)
Number of subjects: 0
Study 37727608 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 0
Study 37727608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase
Number of subjects: 0
Study 37727608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 0
Study 37727636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard North American-type diet for 4 weeks
Number of subjects: 0
Study 37728045 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC + remdesivir
Number of subjects: 664
Study 37728045 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 664
Study 37728115 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs)
Number of subjects: 124
Study 37728115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low psoas muscle index (PMI) (≤5.5409 cm)
Number of subjects: 124
Study 37728115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nutritional index (PNI)
Number of subjects: 124
Study 37728115 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric nutritional risk index (GNRI)
Number of subjects: 124
Study 37728115 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (ALB)
Number of subjects: 124
Study 37728142 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-help plus treatment as usual (TAU)
Number of subjects: 152
Study 37728142 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 152
Study 37728142 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-help plus TAU
Number of subjects: 152
Study 37728224 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate 50 μg once daily (QD)
Number of subjects: 477
Study 37728224 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 477
Study 37728392 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast implants
Number of subjects: 4639
Study 37728392 — intervention group
Group type: EXPERIMENTAL
Intervention: Public mammography screening programme
Number of subjects: 4639
Study 37728406 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) therapy
Number of subjects: 494
Study 37728406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body weight
Number of subjects: 494
Study 37728406 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without epilepsy)
Number of subjects: 494
Study 37728492 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D image-guided robotic-assisted partial nephrectomy (3D-IGRAPN)
Number of subjects: 198
Study 37728492 — intervention group
Group type: COMPARATOR
Intervention: Thermal ablation (TA)
Number of subjects: 198
Study 37728493 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARE Nephrometry Score
Number of subjects: 1171
Study 37728493 — intervention group
Group type: COMPARATOR
Intervention: RENAL Nephrometry Score
Number of subjects: 1171
Study 37728493 — intervention group
Group type: COMPARATOR
Intervention: PADUA Nephrometry Score
Number of subjects: 1171
Study 37728493 — intervention group
Group type: COMPARATOR
Intervention: Tumor Size
Number of subjects: 1171
Study 37728696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (including MPFF, diosmin, compression stockings, creams)
Number of subjects: 6084
Study 37728696 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 6084
Study 37728696 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including MPFF)
Number of subjects: 6084
Study 37728787 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) in the morning (8.00-10.00 h)
Number of subjects: 14
Study 37728787 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the morning (8.00-10.00 h)
Number of subjects: 14
Study 37728787 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) in the evening (17.00-19.00 h)
Number of subjects: 14
Study 37728787 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the evening (17.00-19.00 h)
Number of subjects: 14
Study 37728803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN) at a daily dose of 90 mg for 24 weeks
Number of subjects: 45
Study 37728803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN)
Number of subjects: 45
Study 37728907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg/d)
Number of subjects: 296
Study 37728907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (ENA) on admission, day 3, and day 5
Number of subjects: 172
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)
Number of subjects: 172
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 172
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 172
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid-binding protein 2 (I-FABP2)
Number of subjects: 172
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline
Number of subjects: 172
Study 37728917 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK, leptin, glucagon, I-FABP2, and citrulline
Number of subjects: 172
Study 37728977 — intervention group
Group type: EXPERIMENTAL
Intervention: FHIR-enabled digital PHR app
Number of subjects: 40
Study 37728978 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough Epigenetic Marker Integration Solution (THEMIS) model using cfDNA features (methylated fragment ratio, chromosomal aneuploidy, fragment size index, fragment end motif).
Number of subjects: 360
Study 37728978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of THEMIS model with serological indicators (pepsinogen, gastrin-17, Helicobacter pylori).
Number of subjects: 360
Study 37728978 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care screening.
Number of subjects: 360
Study 37729024 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal sugar-protein balance
Number of subjects: 0
Study 37729033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37729076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 75
Study 37729076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 37729078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpneumatic Active Compression Device
Number of subjects: 0
Study 37729132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions of treatment)
Number of subjects: 60
Study 37729132 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 sessions of treatment)
Number of subjects: 60
Study 37729184 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-0761 (mogamulizumab)
Number of subjects: 49
Study 37729260 — intervention group
Group type: EXPERIMENTAL
Intervention: EASEL Approach (universal educator-delivered practices)
Number of subjects: 16
Study 37729613 — intervention group
Group type: EXPERIMENTAL
Intervention: HCL/HCLv patients with COVID-19
Number of subjects: 503